Sirolimus may not cause neurotoxicity in kidney and liver transplant recipients.
Neurotoxicity associated with calcineurin inhibitors cyclosporin A and tacrolimus is established. Sirolimus is a new agent related to tacrolimus, but its mechanism of action differs. The authors reviewed 202 transplant recipients treated with sirolimus from 2001 to 2004. They found no evidence of neurotoxicity with sirolimus therapy for up to 18 months (range, 15 days to 3 years). Sirolimus could be considered a substitute immunosuppressant for patients with cyclosporin A or tacrolimus neurotoxicity.
Maramattom
Boby V
BV
Division of Critical Care Neurology, Department of Neurology, Mayo Clinic, Rochester, MN, USA. Maramattom.Boby@mayo.edu
Wijdicks
Eelco F M
EF
D000293:Adolescent; D000328:Adult; D000368:Aged; D000369:Aged, 80 and over; D019703:Calcineurin / Q000187:drug effects; D002648:Child; D004359:Drug Therapy, Combination; D005260:Female; D006801:Humans; D007166:Immunosuppressive Agents / Q000008:administration & dosage / Q000009:adverse effects* / Q000097:blood; D016030:Kidney Transplantation; D016031:Liver Transplantation; D016040:Lung Transplantation; D008297:Male; D008875:Middle Aged; D009173:Mycophenolic Acid / Q000031:analogs & derivatives* / Q000627:therapeutic use; D009422:Nervous System Diseases / Q000139:chemically induced* / Q000453:epidemiology; D016035:Pancreas Transplantation; D011183:Postoperative Complications / Q000139:chemically induced*; D011239:Prednisolone / Q000627:therapeutic use; D012189:Retrospective Studies; D020123:Sirolimus / Q000008:administration & dosage / Q000009:adverse effects* / Q000097:blood
D007166:Immunosuppressive Agents; D011239:Prednisolone; D019703:Calcineurin; D009173:Mycophenolic Acid; D020123:Sirolimus